NCT02014389 Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer
| NCT ID | NCT02014389 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sheba Medical Center |
| Condition | Retinal Dystrophies |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2013-12-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2013-12-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objective perimetry can better monitor visual field defects in retinal dystrophy and Glaucoma patients than conventional subjective perimetry. The PLR ( Pupil Light Reflex to short and long wavelength stimuli should be significantly lower compared to healthy participants in areas of visual field defects in retinal dystrophy and Glaucoma patients.
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years old. * Signing informed consent. * Pupillary reflex to light. Exclusion Criteria: 1. Cloudy corneas. 2. Surgical intraocular ophthalmic procedure within the past 30 days. 3. No reactive pupils. 4. Synechia of the iris to the lens after surgery or inflammation. 5. Neovascularization. 6. Axenfeld-Rieger Syndrome. 7. Iris atrophy (ICE syndrome). 8. Iris coloboma. 9. Sphincter damage due to ischemia. 10. Sphincter damage due to trauma (tears of sphincter or diffuse damage to muscle). 11. Sphincter damage due to Herpes Zoster Uveitis. 12. Sphincter damage due to high intraocular pressure. 13. Iris tumor or cyst. 14. Ectropion uvae. 15. Adie's pupil. 16. Third nerve aberrant regeneration of the iris sphincter. 17. RP patients with Optic neuropathy with the potential of producing a positive RAPD (Relative Afferent Pupillary Defect). 18. Chronic use of myotics or mydriatics. 19. Systemic medication that have affect on pupillary reflex . 20. Any condition preventing accurate measurement or examination of the pupil.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02014389 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Retinal Dystrophies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02014389 currently recruiting?
Yes, NCT02014389 is actively recruiting participants. Contact the research team at Ygal.Rotenstreich@sheba.health.gov.il for enrollment information.
Where is the NCT02014389 trial being conducted?
This trial is being conducted at Tel Litwinsky, Israel.
Who is sponsoring the NCT02014389 clinical trial?
NCT02014389 is sponsored by Sheba Medical Center. The trial plans to enroll 200 participants.